Munawwar Hussain

Researcher

UAMS

Also affiliated: Maharishi Markandeshwar University, Mullana (2022); Winthrop Rockefeller Foundation (2022–2023)

Faculty Researcher

6 h-index 13 pubs 95 cited

Research Areas

Biomedical Subjects

Links

ORCID

OverviewAI-generated summary

Munawwar Hussain's research focuses on the clinical outcomes and therapeutic advances in multiple myeloma. His work has investigated CAR-T therapy directed at BCMA in patients with relapsed or refractory multiple myeloma, as well as the use of bone-modifying agents. Hussain has also examined the corneal toxicity associated with belantamab mafodotin and the feasibility of outpatient stem cell transplantation for multiple myeloma patients.

His publications explore various aspects of multiple myeloma treatment, including tandem autologous stem cell transplantation for minimal residual disease and the stem cell origin of cancer. Hussain's scholarship metrics include an h-index of 6 with 93 total citations across 13 publications. He has a significant publication record with key collaborators at the University of Arkansas for Medical Sciences, including Nishanth Thalambedu (10 shared publications), Jaskirat Sethi (9 shared publications), Sravani Gundarlapalli (7 shared publications), and Samer Al Hadidi (7 shared publications). Hussain has been recently active in research, with his most recent publication in 2024.

Metrics

h-index: 6
Publications: 13
Citations: 95

Selected Publications

Stem Cell Origin of Cancer: Clinical Implications beyond Immunotherapy for Drug versus Therapy Development in Cancer Care (2024)

Cancers 2 citations DOI OpenAlex
Differential Diagnosis and Therapeutic Advances in Multiple Myeloma: A Review Article (2023)

Blood and Lymphatic Cancer Targets and Therapy 16 citations DOI OpenAlex
Sixth Nerve Palsy From Multiple Myeloma in Central Nervous System: Case Series and Review of Current Literature (2023)

Cureus 2 citations DOI OpenAlex
Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy (2022)

Bone Marrow Transplantation 22 citations DOI OpenAlex
Clinical Outcome of Patients with Relapsed Refractory Multiple Myeloma Listed for BCMA Directed Commercial CAR T Therapy (2022)

Blood 7 citations DOI OpenAlex
Parameters Influencing Count Recovery Post Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (2022)

Blood DOI OpenAlex
Immunogenicity of Covid-19 Vaccine Among Multiple Myeloma Patients Post Autologous Stem Cell Transplant (2022)

Blood DOI OpenAlex
MM-531 Case Control Study of Outcomes of Autologous Stem Cell Transplantation in Jehovah's Witness Multiple Myeloma Patients (2022)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
Poster: MM-531 Case Control Study of Outcomes of Autologous Stem Cell Transplantation in Jehovah's Witness Multiple Myeloma Patients (2022)

Clinical Lymphoma Myeloma & Leukemia DOI OpenAlex
Corneal toxicity with belantamab mafodotin: Multi‐institutional <scp>real‐life</scp> experience (2022)

American Journal of Hematology 16 citations DOI OpenAlex
The use of bone-modifying agents in multiple myeloma (2022)

Blood Reviews 17 citations DOI OpenAlex
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission (2022)

Journal of Clinical Medicine 13 citations DOI OpenAlex
Tandem autologous stem cell transplantation in patients with persistent bone marrow minimal residual disease after first transplantation in multiple myeloma (2022)

American Journal of Hematology 6 citations DOI OpenAlex